As Biotechnology businesses, Insmed Incorporated (NASDAQ:INSM) and Ophthotech Corporation (NASDAQ:OPHT), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Table 1 shows the top-line revenue, earnings per share and valuation for Insmed Incorporated and Ophthotech Corporation.
Table 2 provides us Insmed Incorporated and Ophthotech Corporation’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
A 1.76 beta means Insmed Incorporated’s volatility is 76.00% more than Standard & Poor’s 500’s volatility. Competitively, Ophthotech Corporation is 14.00% more volatile than Standard & Poor’s 500, because of the 1.14 beta.
Insmed Incorporated has a Current Ratio of 10.1 and a Quick Ratio of 10.1. Competitively, Ophthotech Corporation’s Current Ratio is 13 and has 13 Quick Ratio. Ophthotech Corporation’s better ability to pay short and long-term obligations than Insmed Incorporated.
The next table highlights the shown recommendations and ratings for Insmed Incorporated and Ophthotech Corporation.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
Insmed Incorporated’s upside potential is 16.83% at a $30.4 consensus price target.
Insider & Institutional Ownership
The shares of both Insmed Incorporated and Ophthotech Corporation are owned by institutional investors at 0% and 52.2% respectively. Insiders held roughly 0.9% of Insmed Incorporated’s shares. Competitively, Ophthotech Corporation has 0.57% of it’s share held by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
For the past year Insmed Incorporated has stronger performance than Ophthotech Corporation
Ophthotech Corporation beats Insmed Incorporated on 4 of the 7 factors.
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.